|
|
|
|
| LEADER |
01573nam a22002895i 4500 |
| 001 |
000284550 |
| 005 |
20210519144116.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100727s2010 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781441916037
|
| 024 |
7 |
|
|a 10.1007/978-1-4419-1603-7
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Lipid A in Cancer Therapy /
|c edited by Jean-Francois Jeannin.
|
| 250 |
|
|
|a 1st ed. 2010.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Springer,
|c 2010.
|
| 300 |
|
|
|a 152 p. 20 illus. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in Experimental Medicine and Biology,
|v 667
|
| 505 |
0 |
|
|a Introduction: Historical Background -- Structure andSynthesis of Lipid A -- Conformation and Supramolecular Structure of Lipid A -- Interactions between Lipid A and Serum Proteins -- The Lipid A Receptor -- Lipid A Receptor TLR4-Mediated Signaling Pathways -- Lipid A-Induced Responses In Vivo -- Lipid A-Mediated Tolerance and Cancer Therapy -- Lipid A in Cancer Therapies Preclinical Results -- Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results -- Antitumoral Effects of Lipids A, Clinical Studies -- Conclusion.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
1 |
4 |
|a Biomedicine, general.
|
| 700 |
1 |
|
|a Jeannin, Jean-Francois.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|